You are here

Our science / Clinical Trials / Find a Trial / NCT04171453

Post-marketing Surveillance (PMS) to Observe the Safety and Effectiveness of Lyrica CR Extended Release Tablets

Back to Search Print Save as PDF Bookmark Trial

NCT04171453

Last updated on December 9, 2019
Back to Search Print Save as PDF Bookmark Trial

FOR MORE INFORMATION
Study Location
Contact
1-800-718-1021
[email protected]
Related Links
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Peripheral Neuropathic Pain
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

To be eligible to enter this study, the subject will have to meet the following inclusion
criteria:

1. Korean patients who have been administered Lyrica CR for the first time according to
the current local labeling (indication, dosage and administration).

2. Subjects who have consented to participate in this study by signing the data privacy
statement.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

Patients meeting any of the following criteria will not be included in the study:

1. Patients who have deviated from local labeling (indication, dosage and administration)
in taking this drug

2. Renal impairment patients with CLCr less than 30 mL/min or who are undergoing
hemodialysis.

3. Patients who have hypersensitivity to the active substance (pregabalin) or to any of
the excipients.

4. Other patients who are decided to be not prescribed by the investigator under the
routine medical practice, considering the balance the overall risk and benefit, for
example, patients have suicidal behavior and ideation, or have any risk of these,
and/or patients who are in pregnancy or lactation, etc.

NCT04171453
Pfizer
Not yet recruiting
Post-marketing Surveillance (PMS) to Observe the Safety and Effectiveness of Lyrica CR Extended Release Tablets

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Advanced Search

Based on your search, you may also be interested in

Peripheral Neuropathic Pain
Post-marketing Surveillance (PMS) to Observe the Safety and Effectiveness of Lyrica CR Extended Release Tablets
NCT04171453
All Genders
Descriptive Information
Brief TitlePost-marketing Surveillance (PMS) to Observe the Safety and Effectiveness of Lyrica CR Extended Release Tablets
Official TitlePost-Marketing Surveillance (PMS) To Observe The Safety and Effectiveness of Lyrica (Registered) CR Extended Release Tablets
Brief SummaryThis is an open-label, non-comparative, non-interventional, prospective, and multi-center PMS study to observe safety and effectiveness of Lyrica CR (82.5mg, 165mg, 330mg) in Korean subjects under the actual condition of use. PMS is an obligation to K-MFDS.
Detailed DescriptionNot Provided
Study TypeObservational
Study DesignObservational Model: Other
Time Perspective: Prospective
Target Follow-Up DurationNot Provided
BiospecimenNot Provided
Sampling MethodNon-Probability Sample
Study PopulationSubjects administered with Lyrica CR as a part of routine treatment who comply with the local labeling.
ConditionPeripheral Neuropathic Pain
InterventionDrug: Lyrica CR (Pregabalin)
Lyrica CR 82.5mg, 165mg, or 330mg OD
Study Groups/CohortsOpen-label
This study was open-label with only one treatment group. Lyrica CR was prescribed in accordance with usual clinical practice.
Intervention: Drug: Lyrica CR (Pregabalin)
Publications *Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment StatusNot yet recruiting
Estimated Enrollment
 (submitted: November 19, 2019)		600
Original Estimated EnrollmentSame as current
Estimated Study Completion DateApril 18, 2022
Estimated Primary Completion DateApril 18, 2022   (Final data collection date for primary outcome measure)
Eligibility Criteria

[Inclusion criteria]

To be eligible to enter this study, the subject will have to meet the following inclusion criteria:

  1. Korean patients who have been administered Lyrica CR for the first time according to the current local labeling (indication, dosage and administration).
  2. Subjects who have consented to participate in this study by signing the data privacy statement.

[Exclusion criteria]

Patients meeting any of the following criteria will not be included in the study:

  1. Patients who have deviated from local labeling (indication, dosage and administration) in taking this drug
  2. Renal impairment patients with CLCr less than 30 mL/min or who are undergoing hemodialysis.
  3. Patients who have hypersensitivity to the active substance (pregabalin) or to any of the excipients.
  4. Other patients who are decided to be not prescribed by the investigator under the routine medical practice, considering the balance the overall risk and benefit, for example, patients have suicidal behavior and ideation, or have any risk of these, and/or patients who are in pregnancy or lactation, etc.
Sex/Gender
Sexes Eligible for Study:All
Ages18 Years and older   (Adult, Older Adult)
Accepts Healthy VolunteersNo
Contacts
Contact: Pfizer CT.gov Call Center1-800-718-1021[email protected]
Listed Location CountriesNot Provided
Removed Location Countries  
 
Administrative Information
NCT NumberNCT04171453
Other Study ID NumbersA0081364
Has Data Monitoring CommitteeNot Provided
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product:Yes
Studies a U.S. FDA-regulated Device Product:No
Product Manufactured in and Exported from the U.S.:No
IPD Sharing Statement
Plan to Share IPD:No
Plan Description:Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/da....
Responsible PartyPfizer
Study SponsorPfizer
CollaboratorsNot Provided
Investigators
Study Director:Pfizer CT.gov Call CenterPfizer
PRS AccountPfizer
Verification DateNovember 2019

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now